Cargando…

Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis

Objective: This study aims to investigate the safety and efficacy of abrocitinib in treating moderate-to-severe AD in adolescents and adults. Methods: Pubmed, Cochrane, Embase, and Web of science data base were searched from inception to 9 August 2022. All randomized controlled trials (RCTs) evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ling, Yu, Jiajun, Chen, Baoqing, Guo, Ying, Yang, Yufeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192817/ https://www.ncbi.nlm.nih.gov/pubmed/37214438 http://dx.doi.org/10.3389/fphar.2023.1154949

Ejemplares similares

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
por: Iznardo, Helena, et al.
Publicado: (2023)

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Gao, Qin, et al.
Publicado: (2023)

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial
por: Eichenfield, Lawrence F., et al.
Publicado: (2021)

Efficacy of abrocitinib for atopic dermatitis: a meta-analysis of randomized controlled trials
por: Zhang, Daojun, et al.
Publicado: (2021)

Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Fadlalmola, Hammad Ali, et al.
Publicado: (2021)

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
por: Gooderham, Melinda J., et al.
Publicado: (2023)

High threshold efficacy responses in moderate‐to‐severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents
por: Ständer, S., et al.
Publicado: (2022)

The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data
por: Napolitano, Maddalena, et al.
Publicado: (2021)

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes
por: Cork, M.J., et al.
Publicado: (2021)

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
por: Simpson, Eric L., et al.
Publicado: (2021)

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
por: Thyssen, J.P., et al.
Publicado: (2021)

Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
por: Alexis, Andrew, et al.
Publicado: (2022)

Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
por: Gooderham, Melinda J., et al.
Publicado: (2022)

Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives
por: Niculet, Elena, et al.
Publicado: (2022)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
por: Zhao, Jiahui, et al.
Publicado: (2022)

Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
por: Xu, Xinghua, et al.
Publicado: (2017)

Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series
por: MARESCHAL, Adrien, et al.
Publicado: (2020)

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
por: Simpson, Eric L., et al.
Publicado: (2023)

Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib
por: Soto, Elena, et al.
Publicado: (2020)

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
por: Ständer, Sonja, et al.
Publicado: (2022)

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial
por: Gooderham, Melinda J., et al.
Publicado: (2019)

Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
por: Wang, Junqiao, et al.
Publicado: (2022)

Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
por: Giavina-Bianchi, Mara, et al.
Publicado: (2021)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis
por: Merola, Joseph F., et al.
Publicado: (2023)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
por: Teng, Yan, et al.
Publicado: (2023)

Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized controlled trials
por: Wu, Shuying, et al.
Publicado: (2022)

The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Bashrahil, Bader, et al.
Publicado: (2023)

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
por: Stein Gold, Linda, et al.
Publicado: (2023)

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
por: Simpson, Eric L., et al.
Publicado: (2019)

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2023)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bhtl3gla7ae4r76o0mh79ar01o